Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A Trial.
Trapp EK, Fasching PA, Fehm T, Schneeweiss A, Mueller V, Harbeck N, Lorenz R, Schumacher C, Heinrich G, Schochter F, de Gregorio A, Tzschaschel M, Rack B, Janni W, Friedl TWP. Trapp EK, et al. Among authors: de gregorio a. Cancers (Basel). 2022 Aug 16;14(16):3949. doi: 10.3390/cancers14163949. Cancers (Basel). 2022. PMID: 36010945 Free PMC article.
Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment.
Bauer ECA, Schochter F, Widschwendter P, DeGregorio A, Andergassen U, Friedl TWP, Fasching PA, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Janni W, Rack B, Scholz C; SUCCESS Study Group. Bauer ECA, et al. Breast Cancer Res Treat. 2018 Oct;171(3):571-580. doi: 10.1007/s10549-018-4856-1. Epub 2018 Jun 21. Breast Cancer Res Treat. 2018. PMID: 29931425
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
de Gregorio A, Häberle L, Fasching PA, Müller V, Schrader I, Lorenz R, Forstbauer H, Friedl TWP, Bauer E, de Gregorio N, Deniz M, Fink V, Bekes I, Andergassen U, Schneeweiss A, Tesch H, Mahner S, Brucker SY, Blohmer JU, Fehm TN, Heinrich G, Lato K, Beckmann MW, Rack B, Janni W. de Gregorio A, et al. Among authors: de gregorio n. Breast Cancer Res. 2020 Oct 23;22(1):111. doi: 10.1186/s13058-020-01348-w. Breast Cancer Res. 2020. PMID: 33097092 Free PMC article. Clinical Trial.
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
Trapp E, Janni W, Schindlbeck C, Jückstock J, Andergassen U, de Gregorio A, Alunni-Fabbroni M, Tzschaschel M, Polasik A, Koch JG, Friedl TWP, Fasching PA, Haeberle L, Fehm T, Schneeweiss A, Beckmann MW, Pantel K, Mueller V, Rack B, Scholz C; SUCCESS Study Group. Trapp E, et al. Among authors: de gregorio a. J Natl Cancer Inst. 2019 Apr 1;111(4):380-387. doi: 10.1093/jnci/djy152. J Natl Cancer Inst. 2019. PMID: 30312434 Clinical Trial.
Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study.
Trapp E, Steidl J, Rack B, Kupka MS, Andergassen U, Jückstock J, Kurt A, Vilsmaier T, de Gregorio A, de Gregorio N, Tzschaschel M, Lato C, Polasik A, Tesch H, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Müller V. Trapp E, et al. Among authors: de gregorio n, de gregorio a. Breast. 2017 Oct;35:130-135. doi: 10.1016/j.breast.2017.07.007. Epub 2017 Jul 18. Breast. 2017. PMID: 28732324
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
de Gregorio A, Janni W, Friedl TWP, Nitz U, Rack B, Schneeweiss A, Kates R, Fehm T, Kreipe H, Christgen M, Kümmel S, Trapp E, Wuerstlein R, Hartkopf A, Clemens M, Reimer T, Häberle L, Fasching PA, Gluz O, Harbeck N. de Gregorio A, et al. Br J Cancer. 2022 Jun;126(12):1715-1724. doi: 10.1038/s41416-021-01690-6. Epub 2022 Feb 22. Br J Cancer. 2022. PMID: 35194193 Free PMC article.
Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study.
Deniz M, DeGregorio A, DeGregorio N, Bekes I, Widschwendter P, Schochter F, Ernst K, Scholz C, Bauer EC, Aivazova-Fuchs V, Weissenbacher T, Kost B, Jueckstock J, Andergassen U, Steidl J, Trapp E, Fasching PA, Häberle L, Beckmann MW, Schneeweiss A, Schrader I, Janni W, Rack B, Friedl TW. Deniz M, et al. Breast. 2019 Apr;44:81-89. doi: 10.1016/j.breast.2018.12.008. Epub 2018 Dec 20. Breast. 2019. PMID: 30690254
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer.
De Gregorio A, Friedl TWP, Huober J, Scholz C, De Gregorio N, Rack B, Trapp E, Alunni-Fabbroni M, Riethdorf S, Mueller V, Schneeweiss A, Pantel K, Meier-Stiegen F, Jaeger B, Hartkopf A, Taran FA, Fasching PA, Janni W, Fehm T. De Gregorio A, et al. Among authors: de gregorio n. JCO Precis Oncol. 2017 Nov;1:1-12. doi: 10.1200/PO.17.00023. JCO Precis Oncol. 2017. PMID: 35172510
Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
Polasik A, Tzschaschel M, Schochter F, de Gregorio A, Friedl TWP, Rack B, Hartkopf A, Fasching PA, Schneeweiss A, Müller V, Huober J, Janni W, Fehm T. Polasik A, et al. Among authors: de gregorio a. Geburtshilfe Frauenheilkd. 2017 Dec;77(12):1291-1298. doi: 10.1055/s-0043-122884. Epub 2017 Dec 18. Geburtshilfe Frauenheilkd. 2017. PMID: 29269956 Free PMC article.
118 results